CJC-1295 + DAC

Product Overview

CJC-1295 + DAC is a long-acting synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed to investigate prolonged stimulation of the growth hormone (GH) signalling pathway.

Research involving CJC-1295 has examined its pharmacokinetics and its effects on circulating GH and insulin-like growth factor 1 (IGF-1). The addition of the Drug Affinity Complex (DAC) is associated with substantially extended peptide persistence compared with shorter-acting GHRH-derived peptides.

Research-Chem.uk supplies CJC-1295 + DAC as a laboratory research compound intended strictly for in-vitro and analytical research applications.

What Is CJC-1295 + DAC?

CJC-1295 is a synthetic analogue derived from growth hormone-releasing hormone (GHRH). Unlike native GHRH, which has a relatively short biological duration, CJC-1295 was engineered with modifications intended to increase stability and extend its presence in circulation.

The DAC (Drug Affinity Complex) modification is particularly important to the molecular behaviour of CJC-1295. It enables reversible binding to serum albumin, which contributes to the compound's prolonged pharmacokinetic profile.

CJC-1295 with DAC is identified in chemical databases as a modified GHRH analogue. PubChem lists CJC-1295 with DAC under CAS 446262-90-4, with a reported molecular formula of C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight of approximately 3,647.2 g/mol.

This should be distinguished from CJC-1295 without DAC, which represents a different molecular form and has different reported chemical characteristics.

How Is CJC-1295 + DAC Investigated in Research?

CJC-1295 has primarily been investigated as a tool for studying the regulation of the GHRH–GH–IGF-1 axis. Research has examined how prolonged exposure to the peptide influences:

• Growth hormone secretion
• IGF-1 concentrations
• GH secretory patterns
• Pharmacokinetic behaviour
• Peptide half-life
• GHRH receptor-mediated signalling
• Endocrine feedback mechanisms

One of the key research characteristics of CJC-1295 is its substantially extended pharmacokinetic profile compared with native GHRH. In a controlled human research study, CJC-1295 demonstrated dose-dependent increases in circulating GH and IGF-1, while the estimated peptide half-life was approximately 5.8–8.1 days. Following repeated administration, elevated IGF-1 concentrations were observed for considerably longer periods.

These characteristics have made CJC-1295 a useful research compound for investigating sustained GHRH receptor stimulation.

CJC-1295 + DAC Research Applications

What Does the Research Say?

One of the foundational studies of CJC-1295 investigated its pharmacokinetic and pharmacodynamic characteristics in healthy adults.

Teichman and colleagues reported that a single administration of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations, with effects observed for six days or longer. Mean IGF-1 concentrations increased for approximately 9–11 days, while the estimated half-life of the peptide was 5.8–8.1 days. Following repeated administration, elevated IGF-1 concentrations were observed for considerably longer periods.

A separate study investigated GH secretion during sustained stimulation with CJC-1295. Researchers observed increased basal and mean GH secretion while the characteristic pulsatile nature of GH secretion was maintained. IGF-1 concentrations were also increased.

Together, these studies provide important evidence for the use of CJC-1295 as a research model for investigating prolonged GHRH stimulation and the resulting GH/IGF-1 response.

Importantly, much of the published research has investigated CJC-1295 in controlled experimental settings. Research findings should therefore be interpreted within the specific experimental model in which they were generated rather than extrapolated into unsupported therapeutic claims.

Research References

• Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

  PMID: 16352683  |  DOI: 10.1210/jc.2005-1536

• CJC-1295 — PubChem Compound Database. PubChem CID: 91971820  |  CAS: 446262-90-4  |  Molecular formula: C₁₆₅H₂₆₉N₄₇O₄₆  |  Molecular weight: 3,647.2 g/mol.
• Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Research examining GH secretory patterns and IGF-1 responses following prolonged CJC-1295 stimulation.

Researchers should consult the original publications when assessing experimental methodology, participant populations, endpoints, pharmacological findings and study limitations.

CJC-1295 + DAC Product Specifications

Chemical identification and molecular data are consistent with PubChem's CJC-1295 record.

Quality and Purity

At Research-Chem.uk, analytical quality and batch traceability are central to our research peptide range.

This CJC-1295 + DAC batch is supplied with a stated 98.7% purity, with HPLC analysis used to assess peptide purity. Each batch is supported by a Certificate of Analysis (COA) providing analytical documentation for the supplied material.

Our quality-control approach is designed to give research laboratories greater confidence when selecting peptide materials for controlled laboratory investigations.

Laboratory Research Applications

CJC-1295 + DAC may be suitable for laboratory investigations involving:

• GHRH receptor signalling
• Growth hormone secretion
• IGF-1 signalling
• Endocrine pathway research
• Peptide pharmacokinetics
• Serum protein-binding studies
• Long-acting peptide research
• Analytical peptide chemistry
• In-vitro research models

CJC-1295 + DAC is supplied strictly as a research compound and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

Why Choose Research-Chem.uk?

Research-Chem.uk provides research peptides for laboratories, analytical researchers and other qualified research environments. Our peptide range focuses on: